| Name | Title | Contact Details |
|---|
MHK, part of the Hearst Health network, improves compliance, efficiency and quality for health plans, pharmacy benefit managers and other managed care organizations. We do this by bringing care and knowledge together throughout every member`s care journey. From the beginning, we built MHK on the concept that healthcare reimbursements would be tied to quality instead of fee-for-service—a precursor to today`s value-based healthcare. Today, MHK is a driving force at the center of this transformation. It inspires everything we do. Our vision is to simplify healthcare through technology. Simplifying healthcare with technology creates easier processes, smoother care experiences and more satisfied members. It allows health plans to spend less time on administrative burdens and more time serving those members. That approach allows us to manage tens of millions of lives through some of the most prominent players in healthcare, including 4 of the top 5 and 7 of the top 10 health plans in the country. Unlike other fragmented and disjointed solutions, MHK brings every care moment together. Our technology integrates with core systems, consolidates vital information, streamlines processes and automates workflows based on best practices. We remove the complexity that gets in the way of quality care, so our clients can excel in a changing healthcare environment. Our mission is to serve as a trusted partner, guiding our clients to excel in compliance, improve health outcomes and drive operational efficiencies. MHK equips those we serve with innovative technology that provides critical insights at every stage of care. Alongside that technology, we deliver ongoing guidance and consultative support for our partners` unique needs. With integrated, cloud-based solutions and tailored support on their side, clients can improve member outcomes, quality of care, organizational compliance and business operations at every level.
Businesses are finding themselves faced with transformative change, from cloud technology to big data. No better example than the life sciences industry which is transforming from a data-driven clinical enterprise to an information-driven one. As the EDC specialists OmniComm understands the power that an information-driven clinical enterprise can bring to your clinical research organization. OmniComm is the only company that provides our clients with a choice of best-of-breed EDC platforms that are purpose-built for their unique clinical research environments – Early Phase, Late Phase, Phase I-IV, device trials, Investigator Initiated. We bring the most advanced open and interoperable EDC platforms to our clients; through our innovative cloud technology and advanced API web services we provide our clients with information to make insight driven clinical data-based critical decisions, bringing medical therapies to patients faster with lower risk. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,800 clinical trials. 4 of the 5 top CROs and 7 of the 10 largest Phase I Clinics run OmniComm EDC technologies.
Fora TV is a San Francisco, CA-based company in the Software and Internet sector.
This page is for our fans who want to see the quirky things we’re up to. Follow us as we head out on the road to client sites, tradeshows and other events.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.